BIOA Reports $132.3M Upsized Offering, $19.3M Net Income, +94% YoY Revenue, Phase 1b/2a DME Trial 2026
BioAge Labs, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $17.20
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS